Discourage Using PPIs With New Hep C Med Epclusa

September 2016

Please see the October 2016 FDA advisory about the risk of Hepatitis B reactivation in some patients being treated for Hepatitis C.

New once-daily Epclusa (ep-KLOO-suh, sofosbuvir/velpatasvir) will further simplify outpatient hepatitis C treatment.

Epclusa seems to work as well as other recent hep C meds...can be used for ANY hep C genotype...and patients use just a 12-week course.

But most hep C medications probably won't be on your hospital's formulary due to cost and procurement issues. Epclusa will cost about $75,000 per course...compared to about $55,000 for Zepatier and about $95,000 for Harvoni.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals